Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 97Terminated 32Unknown 9Active not recruiting 6Withdrawn 5Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

venetoclax 38Azacitidine 24fludarabine 20Cytarabine 18Cyclophosphamide 16Specimen Handling 14blinatumomab 13Biopsy 12Busulfan 8Dexamethasone 7Melphalan 6Daunorubicin 6Whole-Body Irradiation 5Vincristine 5Thiotepa 5Methotrexate 5Decitabine 5gilteritinib 4daratumumab 4Tacrolimus 4Stem Cell Transplantation 4Magnetic Resonance Spectroscopy 4Imatinib Mesylate 4Idarubicin 4Exercise 4Blood Specimen Collection 4zanubrutinib 3selinexor 3ruxolitinib 3revumenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Antilymphocyte Serum × Other hematologic neoplasm × Clear all
NCT06238245 2024-02-20

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Beijing 302 Hospital

Phase 2 Not yet recruiting
22 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡